Preferred Label : selegiline;

MeSH definition : A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.; A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.;

MeSH synonym : selegyline; l-deprenyl; selegiline, (r)-isomer;

CISMeF synonym : 2079-54-1 (Selegiline hydrochloride, (R)-Isomer); Bristol-Myers squibb brand of selegiline; bristol myers squibb brand of selegiline; valeant brand of selegiline; selegiline valeant brand; hydrochloride, selegiline;

MeSH hyponym : eldepryl; yumex; selegiline hydrochloride, (R,S)-Isomer; deprenyl; E-250; Selegiline Hydrochloride, (R)-Isomer; emsam; zelapar; selegiline hydrochloride, (S)-Isomer; Jumex; Humex; E 250; E250; Selegiline Hydrochloride;

Related MeSH term : selegiline, (S)-Isomer; selegiline, (R,S)-Isomer; Deprenalin; Deprenil;

MeSH CAS label : benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-;

MeSH Related Number : selegiline hydrochloride, (R,S)-Isomer; selegiline hydrochloride, (S)-Isomer; selegiline, (R,S)-Isomer; selegiline, (S)-Isomer; selegiline hydrochloride, (R)-Isomer; 1205-70-5 (( -)-isomer, HCl); 14611-52-0 (HCl); 2079-54-1 (deprenyl.HCl); 2323-36-6 (cpd without isomeric designation; 4528-51-2 ((S)-isomer); 4528-52-3 ((S)-isomer, HCl); 4530-70-5 (( -)-isomer); deprenyl); 6W731X367Q; 14611-51-9;

Registry Number MeSH : 14611-51-9;

Related CAS MeSH : 1205-70-5 (Selegiline hydrochloride, (R,S)-Isomer); 4528-52-3 (Selegiline hydrochloride, (S)-Isomer); 4530-70-5 (Selegiline, (R,S)-Isomer); 4528-51-2 (Selegiline, (S)-Isomer); 6W731X367Q (Selegiline hydrochloride, (R)-Isomer);

Wikipedia link : https://en.wikipedia.org/wiki/E250;

Is substance : O;

UNII : 2K1V7GP655;

Details


Main resources

You can consult :

A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.

http://www.has-sante.fr/portail/jcms/c_2748724/fr/deprenyl
2017
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
selegiline
Selegiline Hydrochloride, (R)-Isomer
selegiline

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60869007
2012
France
summary of product characteristics
package leaflet
selegiline

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69520633
2012
France
summary of product characteristics
package leaflet
selegiline
tablets

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63585898
2012
France
summary of product characteristics
package leaflet
tablets
selegiline

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69560026
2012
France
summary of product characteristics
package leaflet
selegiline
tablets

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-09/otrasel_ct_5699.pdf
http://www.has-sante.fr/portail/jcms/c_713148/otrasel
http://www.has-sante.fr/portail/jcms/c_1277897/otrasel
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-07/otrasel_20062012_avis_ct11386.pdf
http://www.has-sante.fr/portail/display.jsp?id=c_544969
http://www.has-sante.fr/portail/display.jsp?id=c_399016
2012
France
English
French
selegiline
selegiline
monoamine oxidase inhibitors
antiparkinson agents
administration, sublingual
drug therapy, combination
levodopa
parkinson disease
treatment outcome
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1100390/deprenyl
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-10/deprenyl_-_ct-10335.pdf
2011
France
French
English
evaluation of the transparency committee
selegiline
insurance, health, reimbursement
administration, oral
selegiline
parkinson disease
antiparkinson agents
monoamine oxidase inhibitors

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-11/deprenyl_-_ct-5700.pdf
http://www.has-sante.fr/portail/jcms/c_713112/deprenyl
2008
France
French
selegiline
antiparkinson agents
administration, oral
monoamine oxidase inhibitors
selegiline
parkinson disease
drug therapy, combination
levodopa
treatment outcome
evaluation of the transparency committee

---
https://www.cadth.ca/sites/default/files/pdf/108_No72_selegiline_edrug_f.pdf
2006
Canada
French
administration, cutaneous
selegiline
depressive disorder, major
depression
clinical trials as topic
selegiline
transdermal patch
drug evaluation

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.